溶栓至穿刺时间决定替奈普酶与阿替普酶对大血管闭塞的疗效差异
该多中心回顾性队列纳入1106例接受桥接治疗的大血管闭塞患者,按溶栓至穿刺时间(TTP)分层比较替奈普酶与阿替普酶。替奈普酶组3个月功能独立率优于阿替普酶组(53.6% vs 48.1%;aOR 1.37),该优势集中在TTP<60分钟患者中,表现为早期再通率更高(19.0% vs 9.1%;aOR 2.36)。TTP≥60分钟时两药无显著差异,安全性相当。
要点
- 替奈普酶较阿替普酶改善3个月功能独立(53.6% vs 48.1%;aOR 1.37)。
- TTP<60分钟时替奈普酶早期再通率更高(19.0% vs 9.1%;aOR 2.36)。
- TTP≥60分钟时两药疗效无显著差异,安全性相当。
核心结论
- 替奈普酶相较阿替普酶的再通优势具有时间依赖性,仅在溶栓至穿刺时间<60分钟时显现。
- 尽管时间对功能结局的交互作用未达统计学显著,优化流程实现快速窗口可最大化替奈普酶的潜在获益。
研究设计与样本
- 前瞻性多中心队列的回顾性分析,纳入2022年1月至2025年9月接受替奈普酶或阿替普酶桥接治疗的大血管闭塞患者。
- 1106例接受桥接治疗,1003例纳入主要分析(替奈普酶488例,阿替普酶515例)。
- 按溶栓至穿刺时间(TTP)<60分钟 vs ≥60分钟分层,采用多变量logistic回归校正年龄、基线NIHSS评分和发病至动脉穿刺时间。
主要发现
- 替奈普酶组3个月功能独立率53.6%,阿替普酶组48.1%(aOR 1.37,95%CI 1.03-1.82)。
- TTP<60分钟亚组中,替奈普酶早期再通率19.0% vs 阿替普酶9.1%(aOR 2.36,95%CI 1.32-4.23;Pinteraction=0.047)。
- TTP<60分钟亚组中,替奈普酶功能独立率61.0% vs 阿替普酶49.0%(aOR 1.77,95%CI 1.13-2.77;Pinteraction=0.111)。
- TTP≥60分钟时两药各项结局差异均无统计学显著性。
- 安全性结局相当,但TTP每增加30分钟独立增加两种药物的出血风险。
关键数值与推荐
- 功能独立定义为3个月改良Rankin量表评分0-2分。
- TTP分层界值为60分钟。
临床怎么用
- 在具备条件的中心,应优先选用替奈普酶并优化流程,将溶栓至穿刺时间控制在60分钟以内以最大化再通获益。
- TTP≥60分钟时两药疗效相当,药物选择可综合考虑其他因素。
- 缩短TTP每30分钟均可降低出血风险,应持续优化院内流程。
局限性
- 回顾性分析设计可能存在选择偏倚和混杂。
- 功能结局的时间交互作用未达统计学显著(Pinteraction=0.111),亚组结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tenecteplase improves reperfusion and functional outcomes compared with alteplase in patients with large vessel occlusion. We assessed whether this superiority varies with thrombolysis-to-puncture time (TTP). METHODS: This retrospective analysis of a prospective multicenter cohort included patients with large vessel occlusion who received bridging therapy with either tenecteplase or alteplase between January 2022 and September 2025. Patients were stratified by TTP (<60 versus ≥60 minutes). We subsequently assessed the association of TTP with efficacy and safety outcomes between the alteplase and tenecteplase groups using multivariable logistic regression adjusted for age, baseline National Institutes of Health Stroke Scale score, and time from stroke onset to arterial puncture. Functional independence was defined as a modified Rankin Scale score of 0 to 2 at 3 months. RESULTS: Of 1106 patients who received bridging therapy, 1003 were included in the primary analysis (tenecteplase, 488; alteplase, 515). The median age was 68 (interquartile range, 58-75) years in both groups, with men comprising 64.3% and 66.0%, respectively. Tenecteplase was associated with superior 3-month functional independence compared with alteplase (53.6% versus 48.1%; adjusted odds ratio, 1.37 [95% CI, 1.03-1.82]). This benefit was concentrated in patients with a TTP <60 minutes, where tenecteplase yielded higher rates of both early recanalization (19.0% versus 9.1%; adjusted odds ratio, 2.36 [95% CI, 1.32-4.23]; Pinteraction=0.047) and functional independence (61.0% versus 49.0%; adjusted odds ratio, 1.77 [95% CI, 1.13-2.77]; Pinteraction=0.111). No between-agent differences were significant with TTP ≥60 minutes. Safety outcomes were comparable, but each 30-minute TTP increase independently elevated hemorrhagic risks for both agents. CONCLUSIONS: The recanalization superiority of tenecteplase over alteplase is time-dependent, evident only within a TTP <60 minutes. Although the translation of this advantage into functional outcome was not statistically modified by time, optimizing workflow to achieve this rapid window maximizes the potential benefit of tenecteplase, which should be prioritized in capable settings.
引用
- Wang L, Yang F, Wu X, et al. Thrombolysis-to-Puncture Time Determines the Differential Effect of Tenecteplase Versus Alteplase in Large Vessel Occlusion. Stroke. 2026. PMID: 41953987. doi:10.1161/STROKEAHA.125.054791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。